Exagen Believes Its Computational Method Has An Edge in Emerging Multivariate IVD Market | GenomeWeb
Diagnostic startup Exagen is betting that a technology platform it developed that can identify much smaller sets of genetic markers than its competitors will give it a head start in the race to bring in vitro diagnostic multivariate index assays to market.
The Albuquerque, NM-based company plans to file its first diagnostic, for breast cancer recurrence, with the US Food and Drug Administration as an IVDMIA within the next two months.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.